Vitiligo is widely recognized as a skin condition, but the article says it is often misunderstood as only an aesthetic problem. In fact, it is a chronic autoimmune disease in which the immune system attacks the cells that produce skin pigment. It affects an estimated 0.5% to 2% of the general population, with tens of millions of patients worldwide and about 45,000 in Israel. For about half of patients, it begins before age 20.
The disease causes white patches on the body, often in visible areas such as the face, hands, neck, around the eyes, or around the mouth. It is not contagious and does not threaten life, but its impact on daily life can be substantial. More than 40% of patients in international surveys said it often affects clothing choices, going to beaches or pools, career and study decisions, social avoidance, and intimacy. Many report shame, reduced self-confidence, and sometimes depression, especially when the patches are on exposed areas like the face and hands.
Doctors now stress that severity is not measured only by how much skin is involved. A small patch on the face can be more distressing than a larger patch in a hidden area. Assessment should also include the location, rate of spread, disease activity, and the patient’s personal burden. According to Dr. Mor Pavlovsky, vitiligo is "not only an aesthetic problem" and can affect self-image and mood.
Treatment options have expanded after years in which many patients were told little could be done. Current approaches include anti-inflammatory creams, topical immune-modulating treatments, and phototherapy with controlled ultraviolet light, especially for widespread disease. Repigmentation takes months, not days or weeks, and continued monitoring is needed because the condition can recur or flare.
Recent scientific advances have focused attention on the JAK-STAT pathway. In 2022, the FDA approved the first dedicated vitiligo treatment, a topical JAK inhibitor cream, marking a shift from viewing vitiligo as merely cosmetic to treating it as an autoimmune disease. Clinical trials are now studying oral JAK inhibitors for patients with widespread, active, or highly burdensome disease, including adolescents and adults with nonsegmental vitiligo, with gradual improvement in facial and body pigmentation compared with placebo. On World Vitiligo Awareness Day, observed June 25, the message is that treatment should be individualized and that the outlook is improving.
